Notably, p38 inhibitors appear to offer superior therapeutic outcomes compared to steroids for specific subsets of COPD patients, given that steroids possess limited anti-inflammatory efficacy and are not recommended as standalone treatments for COPD [55, 174]. This evidence concerns the gene MAPK14 and chronic obstructive pulmonary disease.